文献速递神经核医学

临床实践中获取的[18F]-FDOPA PET与[123I]-FP-CIT SPECT在评估临床不确定帕金森综合征患者黑质纹状体变性方面的比较

Comparison of [18F]-FDOPA PET and [123I]-FP-CIT SPECT acquired in clinical practice for assessing nigrostriatal degeneration in patients with a clinically uncertain parkinsonian syndrome.
PubMed 文献 · EJNMMI Res · 2022-10-22

该研究纳入11例临床不确定帕金森综合征(CUPS)患者,均在常规临床诊疗中同时接受[18F]-FDOPA PET和[123I]-FP-CIT SPECT检查,两次扫描中位间隔6个月(范围0-15个月)。9例患者两种检查报告结果不一致,其中7例FDOPA-PET报告正常而DAT-SPECT报告异常。作者认为CUPS患者中DAT-SPECT较FDOPA-PET更常被评为异常,早期患者FDOPA摄取减少可能不如DAT结合减少明显。

要点

  • 11例CUPS患者均在常规临床中接受FDOPA-PET和DAT-SPECT,中位间隔6个月(范围0-15个月)。
  • 9例患者两种检查报告结果不一致,其中7例FDOPA-PET正常而DAT-SPECT异常。
  • CUPS患者中DAT-SPECT较FDOPA-PET更常被评为异常。

核心结论

  • 在这组CUPS患者病例系列中,DAT-SPECT较FDOPA-PET更常被评为异常。
  • 早期CUPS患者中FDOPA摄取的黑质纹状体减少可能不如DAT结合减少明显。
  • 因此常规实践中CUPS患者FDOPA-PET扫描的判读有时具有挑战性。

研究设计与样本

  • 该研究为病例系列,纳入11例临床不确定帕金森综合征(CUPS)患者。
  • 所有患者均在常规临床诊疗中接受FDOPA-PET扫描和DAT-SPECT扫描。
  • 研究比较两种检查的报告结果以评估两种影像技术之间可能存在的差异。

主要发现

  • FDOPA-PET扫描与DAT-SPECT扫描之间的中位间隔为6个月(范围0-15个月)。
  • 9例患者FDOPA-PET与DAT-SPECT报告结果不一致,其中7例FDOPA-PET报告正常而DAT-SPECT报告异常。

关键数值与推荐

  • FDOPA-PET扫描与DAT-SPECT扫描之间的中位间隔为6个月(范围0-15个月)。
  • 11例CUPS患者中9例两种检查报告结果不一致,其中7例FDOPA-PET正常而DAT-SPECT异常。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Two commonly used imaging techniques to aid in the diagnosis of neurodegenerative parkinsonian syndromes are dopamine transporter (DAT) imaging with [123I]-FP-CIT single-photon emission computed tomography (DAT-SPECT) and positron emission tomography with [18F]-FDOPA (FDOPA-PET). This paper provides a unique series of parkinsonian patients who received both FDOPA-PET and DAT-SPECT in routine clinical practice and compares the reported results to assess potential differences between these two imaging techniques. METHODS: We present 11 patients with a clinically uncertain parkinsonian syndrome (CUPS), who received both FDOPA-PET and DAT-SPECT. All patients received an FDOPA-PET scan and DAT-SPECT as part of routine clinical care. RESULTS: The median time between the F-DOPA-PET scan and DAT-SPECT scan was 6 months (range 0-15 months). There was a discrepancy in the reported results of the FDOPA-PET and DAT-SPECT scans in nine patients, including 7 patients whose FDOPA-PET scan was reportedly normal, whereas their DAT-SPECT scan was abnormal. CONCLUSIONS: In this case series of CUPS patients, DAT-SPECT was more often rated as abnormal than FDOPA-PET. The striatal loss of FDOPA uptake can be less pronounced than that of DAT binding in CUPS patients in early disease stages. Consequently, the interpretation of FDOPA-PET scans in CUPS can sometimes be challenging in routine practice.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Wallert E, Letort E, van der Zant F, et al. Comparison of [18F]-FDOPA PET and [123I]-FP-CIT SPECT acquired in clinical practice for assessing nigrostriatal degeneration in patients with a clinically uncertain parkinsonian syndrome. EJNMMI Res. 2022. PMID: 36273088. doi:10.1186/s13550-022-00943-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。